ClinicalTrials.gg

Epidermolysis Bullosa clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 86 studies for Epidermolysis Bullosa across more than 10 countries. 18 are recruiting or about to start. 52 of them are mainly about Epidermolysis Bullosa (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Epidermolysis Bullosa Dystrophica: 148 studies, 33 open.

Status

Completed
43
Recruiting
11
Terminated
8
Active, not recruiting
6
Withdrawn
5
Not yet recruiting
5

Phase

Phase 2
31
Phase 1
17
Phase 3
14
Phase 4
6
Early Phase 1
4

Where

United States
42
France
14
Spain
7
Poland
6
Germany
6
Austria
6

Who develops what

Add Epidermolysis Bullosa to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 5 companies, 4 with this as their studies’ main aim; 3 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Chiesi Farmaceutici and Energenesis Biomedical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
nelitolimod☆ Track2 live phase-3 studies: NCT07482787, NCT07482813paradigm therapeutics
episalvan☆ Track1 live phase-3 study: NCT06917690Chiesi Farmaceutici S.p.A.
birch triterpenesApproved: US 2023☆ Track1 live phase-3 study: NCT06917690Chiesi Farmaceutici S.p.A.

The 3 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.TolaSure Topical Gel · BioMendics, LLC · Phase 2 named, not the main aimNCT07027345 A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex — primary endpoint: Change in Blister Surface Area of the Designated Treatment Area(s) · 40 enrolled
  • 15 Mar 2027 est.ENERGI-F703EB Cream · Energenesis Biomedical Co., Ltd. · Phase 2 main aimNCT07858422 A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa — primary endpoint: Incidence of Local Target Lesion Adverse Events · 24 enrolled
  • 17 May 2027 est.nelitolimod · paradigm therapeutics · Phase 3 main aimNCT07482787 Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa — primary endpoint: Target wound closure · 80 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Epidermolysis Bullosa studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 3

Coming up

8studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger. 10 (91%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (9%) take healthy volunteers.

Recruiting studies that take each age, of 11
AgeWomenMen
1010 (91%)10 (91%)
1810 (91%)10 (91%)
309 (82%)9 (82%)
409 (82%)9 (82%)
509 (82%)9 (82%)
659 (82%)9 (82%)
759 (82%)9 (82%)
859 (82%)9 (82%)

Across all 86 studies, recruiting or not: 29% stop at 75 or younger and 29% at 65; 92% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 86. Browse all 86 → or search them.